A study has uncovered that iron orchestrates the activation of two damaging cell death pathways—ferroptosis and ...
Researchers at Karolinska Institutet have identified a new mechanism that may improve the treatment of ischemic stroke. The ...
The "Stroke - Global Clinical Trials Review, 2025" clinical trials has been added to ResearchAndMarkets.com's offering.The clinical trial report provides an overview of Stroke Clinical trials scenario ...
Phase III PRESTIGE-AF trial shows that direct oral anticoagulants significantly lower the risk of ischemic stroke in ...
A pivotal study has uncovered that iron orchestrates the activation of two damaging cell death pathways—ferroptosis and ...
According to Roche subsidiary Genentech, which announced the label expansion on Monday, TNKase is the first new drug for ...
In 2023, Roche said it was removing TNKase for stroke from its phase 3 programmes after a readout of the TIMELESS trial, but ...
Researchers at Karolinska Institutet have identified a new mechanism that may improve the treatment of ischemic stroke. The ...
News Medical on MSN12h
Research identifies iron as crucial driver of stroke-related cell death processesIschemic stroke continues to rank among the top causes of death and long-term disability globally. While advances in acute treatments like clot retrieval and thrombolysis have improved outcomes, the ...
The U.S. Environment Protection Agency has completed Phase 1 of the hazardous debris removal process in the Los Angeles ...
Zacks.com on MSN8h
Roche Gets FDA Approval for Acute Ischemic Stroke Drug for AdultsRHHBY's member company, Genentech, obtains FDA nod for TNKase (tenecteplase), a thrombolytic or clot-dissolving agent, for the treatment of acute ischemic stroke in adults.
The first phase 3 trial of the injectable hepcidin mimetic, called VERIFY, has met all its primary and secondary objectives, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback